-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Genmab, Raises Price Target to $67

Benzinga·10/29/2026 15:00:49
語音播報
Truist Securities analyst Gregory Renza reiterates Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $67.